Valuation: Pfizer Inc

Market Cap 137B 120B 111B 103B 195B 13,020B 198B 1,327B 516B 6,426B 515B 504B 22,210B P/E 2026 *
11.8x
P/E 2027 * 12.2x
Enterprise Value 186B 163B 150B 139B 265B 17,699B 269B 1,803B 701B 8,735B 700B 685B 30,192B EV / Sales 2026 *
3.02x
EV / Sales 2027 * 3.04x
Free-Float
59.06%
Yield 2026 *
7.27%
Yield 2027 * 7.25%

Last Transcript: Pfizer Inc

Manager TitleAgeSince
Chief Executive Officer 64 2018-12-31
Director of Finance/CFO 60 2022-05-01
Chief Tech/Sci/R&D Officer - 2006-12-31
Director TitleAgeSince
Director/Board Member 68 2007-08-31
Director/Board Member 62 2013-09-26
Chairman 64 2019-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+2.96%+3.01%+59.87%+173.31% 1,102B
+3.05%+5.23%+72.11%+67.81% 643B
-0.04%+1.20%+35.72%+87.93% 450B
+0.65%-2.07%+27.62%+22.57% 336B
-0.99%-0.74%+28.72%+47.97% 288B
-2.98%+1.18%-27.86%-40.73% 222B
+0.45%+1.65%+25.65%+68.35% 199B
+5.21%+7.93%+21.99%+83.23% 169B
-1.39%+5.14%+13.68%+54.43% 133B
Average -0.22%+2.58%+28.61%+62.76% 393.39B
Weighted average by Cap. -0.09%+2.05%+42.48%+90.77%

Financials

2026 *2027 *
Net sales 61.7B 53.99B 49.76B 46.12B 87.55B 5,856B 88.97B 597B 232B 2,890B 232B 227B 9,989B 59.34B 51.93B 47.86B 44.36B 84.21B 5,632B 85.57B 574B 223B 2,780B 223B 218B 9,607B
Net income 11.07B 9.69B 8.93B 8.28B 15.71B 1,051B 15.96B 107B 41.63B 519B 41.56B 40.66B 1,792B 10.72B 9.38B 8.64B 8.01B 15.21B 1,017B 15.45B 104B 40.3B 502B 40.23B 39.36B 1,735B
Net Debt 49.3B 43.14B 39.76B 36.85B 69.96B 4,679B 71.09B 477B 185B 2,309B 185B 181B 7,982B 43.16B 37.77B 34.81B 32.26B 61.24B 4,096B 62.23B 417B 162B 2,022B 162B 159B 6,987B
Logo Pfizer Inc
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (47.4%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (26.2%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (24.5%); - other (1.9%). The United States accounts for 60.8% of net sales.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-